Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore exercitation ullamco…



What Is AmnioFill?

AmnioFill is a placenta-based tissue matrix in a particulate configuration to replace or supplement damaged or inadequate integumental tissue in acute and chronic closures in comorbid patients.

Versatile Tissue Form

  • Replaces or supplements damaged or inadequate integumental tissue
  • Provides a human biocompatible extracellular matrix

Retains Regulatory Proteins

300+ regulatory proteins1-3

Product Advantages

  • SMR2T Technology and patented Purion® processing
  • Terminally sterilized for additional level of safety
  • Easy to apply
  • Room temperature storage
  • 5-year shelf life
  • Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)

Clinical Use Examples

  • Comorbid patients with complex defects or delayed healing
  • Diabetic foot ulcers (DFUs)
  • Venous leg ulcers (VLUs)
  • Debridements
  • Decubitus ulcers

Product Details

AmnioFill is processed using Purion, a unique patented method for placental-based allografts that is in accordance with the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized. AmnioFill is SMR2T Technology (Selective Membrane of Reparative and Reconstructive Tissue)
1. Koob, et al. J Biomed Mater Res B Appl Biomater. 2014 Aug;102(6):1353-62. 2. Lei, et al. Adv Wound Care. 2017 Feb 1;6(2):43-53. 3. MM-RD-00086, Proteome Characterization of Purion Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and Purion Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts.

Contact us for more information about AmnioFill

AmnioFill Product Sheet